Group items tagged

Note that the expressions of malignancy and cancer are also used to describe cancer. The benign tumor is not cancerous, and is less health. It can put pressure on an organ or tissue, but in a limited space and does not spread in the body. Prevalence

They include oral, throat and sinus cancers. These are generally related to lifestyle habits, specifically, the use of tobacco and alcohol. The remaining 20 per cent of head and neck cancers are cancers of the thyroid, salivary glands, lymphomas, sarcomas and skin cancers and are not lifestyle related. India has one of the highest incidences of head and neck cancers in the world. Around four lakh such cancers are newly diagnosed here every year.

Breast cancer can be easily placed at the top of life threatening diseases in the world as it accounts for almost 26 % of all cancer cases in the world and it is the largest killer of people in the world after lungs cancer. Despite of the cruel facts about this type of cancer reasons, mechanisms and treatment of breast cancer are still shrouded and it can't be said for sure that what causes this cancer and what treatment options can be best used to get rid of it.

A cancer registry is the cancer cases which are registered in a population or specific country. In whole world mortality rate due to cancer is 20%. In USA cancer is the second largest disease of causing death after heart disease. Recently in 2016 estimated that 595,690 people die from this disease according to cancer statistics of National Cancer Institute USA.

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday (November 29) as it seeks to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research. Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to target and kill cancer cells. Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells.

NICE has recommended use of tucatinib as an option to treat HER2-positive breast cancer that has spread in people who have already tried 2 or more anti-HER2 treatments. The move is set to benefit around 400 people with advanced breast cancer. Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. The medicine is taken as two 150 mg tablets twice daily along with anti-cancer medicines trastuzumab and capecitabine. Helen Knight, programme director in the NICE Centre for Health Technology Evaluation, said: "Unfortunately there is no cure for breast cancer that has spread to other parts of the body. There is also a lack of additional anti‑HER2 treatments which can postpone the need for chemotherapy, especially for people whose cancer has spread to their brain because their treatment options are even more limited.

Community pharmacies in England could soon be allowed to make cancer referrals to hospitals under new plans to improve early detection of the disease. An NHS pilot scheme, which starts later this year as a pilot in an undisclosed number of places of England, will see community pharmacy staff spotting signs of cancer in people who might not have noticed symptoms. Pharmacy teams will be trained to spot red flags, such as patients with symptoms such as a cough that lasts for three weeks or more, difficulty swallowing or blood in their urine, and send them for scans and checks without needing to see a GP if they think it could be cancer. Amanda Pritchard, the NHS chief executive, will unveil the plans at the NHS Confed Expo conference in Liverpool on Wednesday (June 15), and say: "These plans have the power to truly transform the way we find and treat cancer, and ultimately spare thousands of patients and their families from avoidable pain and loss." The plans include new "roaming liver trucks" - which will be parked near GP surgeries, in town centres and food banks - to encourage people most at risk of getting liver cancer to get "on the spot scans" for diagnosis.

Learning about breast cancer can be of great assistance to catch it earlier because earlier detection leads to the better treatment. Women breasts are composed of an intricate network of ducts and lobes protected by fatty tissues. When cancer develops breast cells continue to multiply and divide in an abnormal speed. The cancer develops into the ducts and lobes at times and if it confines to the place of origin it is called non-invasive cancer and when it spreads to other parts of the body it is called invasive because it starts affecting the lymph nodes and other parts of the body as well, however non-invasive cancer can be treated easily because it is called primary cancer.

The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials. The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients. David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care. "We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.

The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system. Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication, particularly for individuals from Mixed, Black, or Asian backgrounds. Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals before receiving a cancer diagnosis. Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across the population. These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience. Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.

Breast cancer awareness is one of the most crucial things for women of the present world as breast cancer has become one of the leading causes to kill a number of women each year. It is just the understanding of breasts so that abnormal changes can be detected as they take place otherwise they can become the reason of serious health issues. As breast cancer affects the women in every corner of the world so there must be a method to prevent this disease, however many studies have been conducted to fulfill this purpose but no such way has been introduced yet so it is advised to women that stay in touch with breasts on regular basis to be breast aware. Breast awareness not only helps in understanding the breast structure, but also helps in early detection of breast cancer on primary stage when it is easier to treat and control.

Breast cancer is one of the most common and aggressive types of cancer, and according to the statistics, about 16% of total number of deaths from cancer are accounted to this one. Scientists and medical specialists around the world are urgently looking for effective solutions and remedies for breast cancer, and recently one of the researches ended up with promising positive results. A group of scientists from Texas AgriLife Research Lab found out that extracts of peaches and plums can destroy breast cancer cells

The UK's National Health Service (NHS) has partnered with P-Wave, a urinal products brand, to put cancer warnings for men on urinal mats in public places across England, as part of its new earlier diagnosis drive. Urinal mats in pubs, restaurants, shops, hotels and sports stadiums will begin to carry the message "Blood in your pee? Contact your GP practice", and men's toilets in workplaces will also be targeted, the NHS said. Health chiefs believe that this unique initiative will help men to spot the signs of cancer such as blood in pee, and catch the disease early. "Having blood in your pee - even just once - shouldn't be ignored because it can be a sign of cancer, so it needs to be checked out by your GP team," said Professor Peter Johnson, NHS England National Clinical Director for Cancer.

Colon cancer is the cancer of the lower part of the digestive system called the large Intestine or Colon & Balanced Diet and Regular Exercise Curtails Colon Cancer

Colon cancer is the cancer of the lower part of the digestive system called the large Intestine or Colon & Balanced Diet and Regular Exercise Curtails Colon Cancer

National Institute for Health and Care Excellence (NICE)'s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July). Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway. The new draft guidance will now see everyone receive a FIT. A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation. Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer. The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer. The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist. The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.

Benefits of Echinacea for Health and Wellness The Echinacea plant is still in benefit today as a dietary supplement. It has nine species, but only two of them, Echinacea purpurea and Echinacea angustifolia are generally used in supplements. Other supplements are in pill form, teas, juices, and creams. It possesses many compounds that may benefit your health. 1/10_ It treat infections and wounds Echinacea has been used for centuries to treat infections and wounds. In fact, the Native Americans used echinacea to treat their cuts, burns, bruises, and insect bites. They'd apply the fresh plant directly onto their skin to heal those wounds faster than they would have otherwise. It has also been shown in multiple studies to be effective in treating colds and other infections. This benefit is believed to be due to its immune-boosting properties that help strengthen your body's defenses against bacteria. ECZEMA People with eczema suffer from an inflammation of the skin; a cream including echinacea extract may benefit. Early research suggests that daily topical application of echinacea cream helped alleviate eczema-related irritation. It also helped create the protective outer layer of skin. Be aware of probable allergic reactions, as people with eczema generally have allergies and asthma. 2/10_Antioxidant powerhouse Antioxidants are substances that protect you from disease by neutralizing or eliminating the damaging effects of free radicals. Free radicals are atoms, molecules, or ions in your body that have an unpaired electron and can cause oxidative stress in your cells. Echinacea is a powerful antioxidant that helps fight the free radicals that cause damage to cells and tissues. Free radicals may contribute to cancer development, cardiovascular disease, arthritis, diabetes mellitus, Alzheimer's disease, and many other chronic diseases. Echinacea has been shown in studies to positively impact the immune system by boosting its response against infection-causing

NHS England has expanded its national bowel screening programme to people aged 54 so that cancers can be detected at an earlier stage when they are easier to treat. As part of the expansion, the health service would be sending a home-testing kit for bowel cancer, known as the Faecal Immunochemical Test (FIT), to thousands more people in the North West. Those who are eligible (aged 54 and over) will now automatically receive the kit every two years by post, enabling them to self-check for blood in stool samples, which can be a sign of bowel cancer. With the expansion of the NHS Bowel Cancer Screening Programme to people aged 54 years, an additional 830,000 people in England will now be eligible for the screening test.